Helus Pharma shares fell 22% in pre-market trading despite strong Phase 2 results for its anxiety drug HLP004. The trial showed a 10.4-point drop in anxiety scores for patients receiving a 20-mass dose alongside standard care. The study showed a 67% clinical response rate. Investors are likely buying the dip.